Cargando…

Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial

BACKGROUND: COX-2 inhibitors, such as celecoxib, and ubiquitin-proteasome pathway inhibitors, such as bortezomib, can down-regulate NF-κB, a transcription factor implicated in tumor growth. The objective of this study was to determine the maximum tolerated dose and dose-limiting toxicities of bortez...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hayslip, John, Chaudhary, Uzair, Green, Mark, Meyer, Mario, Dunder, Steven, Sherman, Carol, Salzer, Shanta, Kraft, Andrew, Montero, Alberto J
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2007
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2234426/ https://www.ncbi.nlm.nih.gov/pubmed/18053191 http://dx.doi.org/10.1186/1471-2407-7-221

Ejemplares similares

Phase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer
por: Beldner, Matthew A, et al.
Publicado: (2007)

Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor
por: Dudek, A Z, et al.
Publicado: (2009)

Tumor suppressor gene methylation in follicular lymphoma: a comprehensive review
por: Hayslip, John, et al.
Publicado: (2006)

Sequential treatment with celecoxib and bortezomib enhances the ER stress-mediated autophagy-associated cell death of colon cancer cells
por: Park, Ga-Bin, et al.
Publicado: (2018)

Combination of celecoxib with percutaneous radiotherapy in patients with localised prostate cancer – a phase I study
por: Ganswindt, U, et al.
Publicado: (2006)

Cytokinesis-block micronucleus assay of celecoxib and celecoxib derivatives
por: Reimann, Hauke, et al.
Publicado: (2020)

Impact of HPMCAS on the Dissolution Performance of Polyvinyl Alcohol Celecoxib Amorphous Solid Dispersions
por: Monschke, Marius, et al.
Publicado: (2020)

A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies
por: Harvey, R D, et al.
Publicado: (2013)

Preoperative chemoradiotherapy using S-1 combined with celecoxib for advanced lower rectal cancer: Phase I/II study
por: Ohira, Gaku, et al.
Publicado: (2019)

Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma
por: Mateos, María Victoria, et al.
Publicado: (2022)

[(123)I]-Celecoxib Analogues as SPECT Tracers of Cyclooxygenase-2 in Inflammation
por: Uddin, Md. Jashim, et al.
Publicado: (2010)

Bortezomib
por: Rajappa, Senthil
Publicado: (2010)

Preparation and characterization of celecoxib solid dispersions; comparison of poloxamer-188 and PVP-K30 as carriers
por: Homayouni, Alireza, et al.
Publicado: (2014)

Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer
por: Del Rivero, Jaydira, et al.
Publicado: (2018)

Progress on the Application of Bortezomib and Bortezomib-Based Nanoformulations
por: Liu, Jianhao, et al.
Publicado: (2021)

Celecoxib Analogues for Cancer Treatment: An Update on OSU-03012 and 2,5-Dimethyl-Celecoxib
por: Sobolewski, Cyril, et al.
Publicado: (2021)

Characterization of bortezomib-adapted I-45 mesothelioma cells
por: Zhang, Lidong, et al.
Publicado: (2010)

Modulation of genomic and epigenetic end-points by celecoxib
por: Izzotti, Alberto, et al.
Publicado: (2018)

Assessment of lipophilicity of newly synthesized celecoxib analogues using reversed-phase HPLC
por: Elmansi, Heba, et al.
Publicado: (2019)

The ubiquitin–proteasome system as a molecular target in solid tumors: an update on bortezomib
por: Milano, A, et al.
Publicado: (2009)

Phase I Study of a Combination of Fluvastatin and Celecoxib in Children with Relapsing/Refractory Low-Grade or High-Grade Glioma (FLUVABREX)
por: Leblond, Pierre, et al.
Publicado: (2023)

Challenges and Opportunities for Celecoxib Repurposing
por: Bąk, Urszula, et al.
Publicado: (2023)

Preparation and Evaluation of Amino Acid Conjugates of Celecoxib as Prodrugs to Improve the Pharmacokinetic and Therapeutic Properties of Celecoxib
por: Lee, Yonghyun, et al.
Publicado: (2020)

Formulation, Characterization, and in Vivo Evaluation of Celecoxib-PVP Solid Dispersion Nanoparticles Using Supercritical Antisolvent Process
por: Ha, Eun-Sol, et al.
Publicado: (2014)

A famciclovir + celecoxib combination treatment is safe and efficacious in the treatment of fibromyalgia
por: Pridgen, William L, et al.
Publicado: (2017)

Evaluation of Different Techniques for Size Determination of Drug Nanocrystals: A Case Study of Celecoxib Nanocrystalline Solid Dispersion
por: Kaur, Amanpreet, et al.
Publicado: (2019)

Celecoxib-Loaded Solid Lipid Nanoparticles for Colon Delivery: Formulation Optimization and In Vitro Assessment of Anti-Cancer Activity
por: Alajami, Hamdan N., et al.
Publicado: (2022)

Triggering of Suicidal Erythrocyte Death by Celecoxib
por: Lupescu, Adrian, et al.
Publicado: (2013)

Reappraisal of the Therapeutic Role of Celecoxib in Cholangiocarcinoma
por: Yeh, Chun-Nan, et al.
Publicado: (2013)

Celecoxib in breast cancer prevention and therapy
por: Li, Jieqing, et al.
Publicado: (2018)

The molecular mechanisms of celecoxib in tumor development
por: Wen, Bin, et al.
Publicado: (2020)

Combination of fasudil and celecoxib promotes the recovery of injured spinal cord in rats better than celecoxib or fasudil alone
por: Hou, Xiao-lin, et al.
Publicado: (2015)

Phase I Study of Celecoxib with Concurrent Irinotecan, Cisplatin, and Radiation Therapy for Patients with Unresectable Locally Advanced Non-Small Cell Lung Cancer
por: Komaki, Ritsuko, et al.
Publicado: (2011)

Randomized, placebo‐controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib
por: Richardson, Paul G., et al.
Publicado: (2020)

Celecoxib treatment does not alter recruitment and activation of osteoclasts in the initial phase of experimental tooth movement
por: Carvalho-Filho, E.P., et al.
Publicado: (2012)

Subcutaneous Administration of Bortezomib: Strategies to Reduce Injection Site Reactions
por: Kurtin, Sandra, et al.
Publicado: (2012)

Development and Evaluation of Poorly Water-Soluble Celecoxib as Solid Dispersions Containing Nonionic Surfactants Using Fluidized-Bed Granulation
por: Kwon, Hyeok Jin, et al.
Publicado: (2019)

Bortezomib in Kidney Transplantation
por: Raghavan, Rajeev, et al.
Publicado: (2010)

Pharmacokinetics of multiple doses of co‐crystal of tramadol–celecoxib: findings from a four‐way randomized open‐label phase I clinical trial
por: Videla, Sebastián, et al.
Publicado: (2017)

A phase 2 study of bortezomib, cyclophosphamide, pegylated liposomal doxorubicin and dexamethasone for newly diagnosed multiple myeloma
por: Becker, P S, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_292dof992e26b7qfunhaes2ins